Cantor Fitzgerald keeps Overweight on Elevance Health stock
Published on 10/09/2026 at 16:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Cantor Fitzgerald maintained an Overweight rating and a USD 450.00 price target after Elevance Health's 2027 Medicare Stars results.
- The Medicare Stars rating fell to 47.00 percent in 2027 from 54.00 percent in 2026.
- Elevance Health reported adjusted earnings per share of USD 7.45 versus USD 6.21 consensus in the second quarter of 2026.
- Elevance Health stock was trading at EUR 369.70 at Lang & Schwarz on October 9, 2026, plus 2.17 percent versus the prior close.
Elevance Health (ISIN US0367521038) was trading at EUR 369.70 at Lang & Schwarz on October 9, 2026 at 4:15 p.m. CEST, up 2.17 percent versus the prior close of EUR 361.85. On October 9, Cantor Fitzgerald maintained an Overweight rating and a USD 450.00 price target after Elevance Health's 2027 Medicare Stars ratings were released, as Investing.com reported. The immediate issue is not the target itself but whether Medicare Advantage execution can support the earnings recovery.
Three dated earnings signals
On July 15, 2026, Elevance Health reported USD 49.83 billion in second-quarter revenue and adjusted earnings per share of USD 7.45, versus USD 6.21 consensus, according to MarketBeat. On September 10, 2026, the company reaffirmed adjusted 2026 earnings guidance of at least USD 27.00 per diluted share, as Investing.com reported. On October 9, 2026, Cantor Fitzgerald kept its USD 450.00 target while highlighting the 47.00 percent 2027 Stars rating against 54.00 percent in 2026.
What does the Stars result mean?
The Medicare Stars comparison gives investors a concrete counterweight to the second-quarter earnings beat. Cantor Fitzgerald said the result could pressure the stock through greater caution around Medicare Advantage management, while still expecting Elevance Health to beat third-quarter 2026 results, according to Investing.com. The 7.45 adjusted earnings per share result therefore supports the recovery case, but the 47.00 percent Stars rating keeps operating risk visible.
Analyst targets and reporting date
Barclays raised its price target from USD 457.00 to USD 469.00 on October 7, 2026 and retained an Overweight rating, according to Markets Insider. StreetAlpha lists the next Elevance Health earnings report for October 21, 2026, with a consensus revenue estimate of USD 49.32 billion and consensus earnings per share of USD 4.69, according to StreetAlpha. Those estimates set the next measurable test for the guidance floor and the Medicare Advantage concerns.
Euro quote rises into earnings
On the NYSE, Elevance Health was last at USD 413.54 on October 9, 2026 at 10:27 a.m. ET, while its 52-week range stood at USD 274.84 to USD 436.24. The Lang & Schwarz euro quote was EUR 369.70 at 4:15 p.m. CEST on October 9, 2026, plus 2.17 percent versus the EUR 361.85 prior close on October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of Elevance Health stock.
Elevance Health stock facts
- Company: Elevance Health Inc.
- ISIN: US0367521038
- Ticker: ELV
- Primary exchange: NYSE
- Price Lang & Schwarz as of October 9, 2026, 4:15 p.m. CEST: EUR 369.70
- Change versus prior close: plus 2.17 percent
- Prior close Lang & Schwarz October 8, 2026: EUR 361.85
- Market capitalization: USD 89.7 billion as of October 9, 2026
- 52-week range: USD 274.84-436.24 as of October 9, 2026
- Sector / Industry: Healthcare / Medical - Healthcare Plans
- Next earnings date: October 21, 2026
Market context: Market report S&P 500.
